HIV

Gilead Sciences Women HIV Movement campaign
Favicon Fierce Biotech

JPM26: Gilead eyes new deals from a 'position of strength'

Across virology, oncology and inflammation, Gilead has "the luxury of being selective" in the external assets it considers adding to its pipeline.
Darren Incorvaia Jan 14, 2026 3:30am
HIV AIDS PREP
Favicon Fierce Biotech

Study finds HIV can evolve to resist lenacapavir—at a cost

Jan 7, 2026 2:00pm
Gilead

Gilead's single-tablet HIV combo passes 2nd late-stage test

Dec 16, 2025 9:15am
Gilead

Gilead's bictegravir, lenacapavir tablet meets mark in phase 3

Nov 13, 2025 9:55am
Gilead

Gilead lifts guidance on PrEP launch despite cell therapy woes

Oct 31, 2025 11:51am
Surescripts settlement commentary

Gilead inks Biktarvy settlements with 3 generic drug makers

Oct 7, 2025 7:40am